Allogene Therapeutics, Inc. has disclosed a recent transaction involving the sale of shares by an officer, Geoffrey Parker. The sale, which took place on October 21, 2026, involved 36,342 shares of common stock, valued at approximately $48,698.28. This transaction follows the vesting of restricted stock units awarded to Parker as part of the company's equity compensation plan. Such moves are common in the biological products sector, where companies often reward executives with stock options.
Background
Allogene Therapeutics, Inc. operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company is listed on the Nasdaq under the ticker symbol ALLO. As a smaller reporting company, Allogene is classified as a non-accelerated filer, which influences its reporting requirements. The company is headquartered at 210 East Grand Avenue, South San Francisco, CA.
What the Filing Says
The filing indicates that Parker sold the shares on October 21, 2026, after acquiring them through the vesting of restricted stock units. The document states, "The nature of acquisition transaction: Vesting of restricted stock unit award." This highlights the company's ongoing practice of compensating its executives through equity.
Impact
This transaction may affect various stakeholders, including investors and employees. Investors often scrutinize officer share sales as indicators of confidence in the company’s future. Employees may view such transactions as a benchmark for their own compensation and equity opportunities.
What's Next
The filing does not say what happens next.